Dendreon: Righting The Ship

By Saul Kerpelman:One of the challenges facing Dendreon Corporation (DNDN) as it attempts to recover from its recent slide is the need to respond to and correct the virtual torrent of misinformation that has attended the Provenge story.

By Osman Gulseven:Investing in Dendreon (DNDN) is a risky business. The company currently relies only on one product: Provenge. While Dendreon has a few drug candidates in the pipeline, the timeline for FDA submission is uncertain.

By Saul Kerpelman:In a matter of mere months Dendreon Corporation (DNDN) has gone from being the Darling of the Biotech World, with every small biotech avidly hoping and striving to be "The Next Dendreon"--even as Dendreon's advocates had long hoped for it to be the fabled "Next Amgen"--to being a pariah whose shares have lost roughly 80% of their value.

By The Swiss Trader:Until just recently, immunotherapy (or stimulation of the immune system to treat disease) was regarded as an ill-conceived approach in cancer drug development. Many scientists and investors did not consider immunotherapy treatment to be a legitimate area of cancer research. The skepticism was not totally unfounded as there had been years of failures, such as those from CancerVax, IDM, and Cell Genesys to name a few.

By Andrew J. Norris: Unlike chemotherapy, which directly attacks cancer cells, immunotherapy stimulates a patient's immune system to attack tumors and ultimately prolong survival. Autologous cellular immunotherapy, such as Dendreon's (DNDN) sipuleucel-T (Provenge), uses patients' own immune cells to defend against cancer as these cells are best known as nature's adjuvants and are very powerful in eliciting an immune response.

By Saul Kerpelman:Back on November 7, 2011, I wrote about Dendreon Corporation (DNDN) and what I called the "Market Mania" surrounding its "slow" launch of Provenge, the first FDA approved immunotherapy for the treatment of advanced prostate cancer.

By VFC: When the entire biotechnology sector looked to have taken a downturn all at the same time a couple of months ago, many pointed fingers at Dendreon (DNDN), whose shares plummeted after announcing a complete revision of 2011 sales guidance for Provenge.

Andrew Wilkinson submits: